MCAT topics → Gene Expression — Gene to Protein → Gene Therapy and CRISPR

Gene Therapy and CRISPR

Gene therapy and CRISPR sit at the intersection of molecular biology and medicine, and the MCAT tests them primarily through passage-based questions about experimental design and predicted outcomes. The most commonly confused distinction: knockout, knockdown, and knock-in are not synonyms. Knockout is permanent disruption at the DNA level; knockdown is transient reduction at the RNA level that reverses when the interfering RNA degrades; knock-in is sequence insertion. Confusing these will send you down the wrong path on multi-question passage sets.

What makes this topic tricky is that several terms sound interchangeable but are mechanistically distinct. Knockout, knockdown, and knock-in each operate at different molecular levels and have different permanence — conflating them will cost you on experimental interpretation questions. Similarly, CRISPR specificity confuses a lot of students because Cas9 is the flashy enzyme that does the cutting, so students assume it's also doing the targeting. It's not. The guide RNA does that job, and the MCAT will absolutely probe whether you understand that distinction.

This is a low-yield topic overall, but when it appears, it tends to show up in research-design passages where one wrong assumption about mechanism sends you down the wrong path for multiple questions. Nail the conceptual differences between the approaches and you'll handle whatever the exam throws at you.

Common misconceptions

Common mistake
Gap: Unaware that retroviral vs lentiviral vectors differ in ability to transduce non-dividing cells
Retroviruses integrate into the host genome only in dividing cells, whereas lentiviruses can integrate in non-dividing cells, making lentiviruses preferable for targeting neurons or muscle.
Classic retroviruses require nuclear envelope breakdown — which only happens during cell division — to access the host genome and integrate. Lentiviruses (a subclass of retroviruses, like HIV) have evolved machinery to actively transport their pre-integration complex into the nucleus through intact nuclear pores, so they can infect non-dividing cells like neurons, muscle fibers, and macrophages. This distinction matters clinically: if the target tissue is post-mitotic, a retroviral vector simply won't work, and lentiviral vectors are the right choice.
Common mistake
Wrong: Cas9 protein alone scans the genome and cuts at any double-stranded DNA site.
Right: Cas9 requires a guide RNA (gRNA) complementary to the target sequence to direct it to the correct genomic locus before making a double-strand break.
Cas9 on its own has no inherent sequence specificity — it's essentially a programmable molecular scissors that needs instructions. The guide RNA (gRNA) provides those instructions by base-pairing with a specific ~20-nucleotide sequence in the genome, bringing Cas9 to exactly that location. Without the gRNA, Cas9 cannot find its target; change the gRNA sequence and you redirect Cas9 to an entirely different genomic site. The exam will use this to test whether you understand that CRISPR's precision is RNA-based, not protein-based.
Common mistake
Wrong: Gene knockout and gene knockdown both permanently eliminate gene function through DNA deletion.
Right: Knockout permanently disrupts the gene at the DNA level (e.g., via CRISPR), while knockdown transiently reduces gene expression at the RNA level (e.g., via siRNA) without altering the DNA sequence.
The key axis here is DNA vs. RNA and permanent vs. transient. Knockout operates at the genome level — CRISPR introduces a double-strand break that gets repaired imprecisely (via NHEJ), introducing mutations that permanently disable the gene in that cell and all its descendants. Knockdown leaves the DNA untouched and instead degrades or blocks mRNA (via siRNA, shRNA, or antisense approaches), reducing protein output temporarily — once the interfering RNA degrades, expression can recover. If a passage describes a treatment that reverses after a few weeks, that's knockdown, not knockout.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the major viral vector types used in gene therapy — retroviruses, adenoviruses, and lentiviruses — and understand key differences like genome integration vs. episomal expression and the ability to transduce dividing vs. non-dividing cells.
  2. Understand the CRISPR-Cas9 mechanism at a mechanistic level: the guide RNA base-pairs with the target DNA sequence, and only then does Cas9 make a double-strand break — specificity comes from the gRNA, not the protein itself.
  3. Be able to distinguish gene knockout (permanent disruption at the DNA level), gene knockdown (transient reduction at the RNA level via siRNA or similar), and knock-in (insertion of a new sequence) based on their mechanisms and expected experimental outcomes.
  4. Given a passage describing a gene therapy experiment or clinical application, identify whether the approach is somatic or germline, predict likely outcomes or limitations, and evaluate the appropriateness of the delivery strategy for the target tissue.

Can you avoid these mistakes?

A researcher wants to deliver a therapeutic gene to neurons in the brain, which are post-mitotic. She is choosing between a classical retroviral vector and a lentiviral vector. Which should she choose and why?
In a CRISPR experiment, a lab synthesizes a mutant Cas9 that can no longer bind guide RNA but retains its nuclease domains. What would happen if this mutant Cas9 is introduced into cells — would it cut DNA at the intended target? Explain your reasoning.
An experiment uses siRNA to reduce expression of a tumor suppressor gene in cultured cells. A colleague describes this as 'knocking out' the gene. Is this description accurate? What would need to be done differently to achieve a true knockout?
A passage describes a gene therapy trial in which a corrective gene is delivered via adenoviral vector to the liver. Patients show restored enzyme activity for several months, but levels decline over time without any immune response detected. What is the most likely explanation for the decline, given what you know about adenoviral vectors versus integrating vectors?

Related topics

Recombinant DNA, PCR, Cloning, and Gel Electrophoresis Nucleotide and Nucleic Acid Structure DNA Double Helix and Base Pairing DNA Replication (Semiconservative, Enzymes, Fork) DNA Repair Pathways

See how your Anki deck covers this topic.

Upload your deck for a free audit →